Article

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664

02/21/2024

RP-1664 is a Potential First-in-Class, Selective, PLK4 Inhibitor Excerpt from the Press Release: CAMBRIDGE, Mass. & MONTREAL–(BUSINESS WIRE)–Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company’s Phase 1 LIONS (PLK4 Inhibitor in Advanced Solid Tumors) clinical trial evaluating…

Read More

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004

02/20/2024

— Activation of four U.S. sites for Phase 1 clinical trial of PAS-004 to evaluate safety, dose, key biomarker data and preliminary efficacy — — Plans to open three additional sites in Eastern Europe in the coming months — — Preliminary interim data expected in 2H 2024 — Excerpt from the Press Release: SOUTH SAN…

Read More

Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer

02/19/2024

Excerpt from the Press Release: BOSTON, Feb. 14, 2024 (GLOBE NEWSWIRE) — Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced that the first patient has been dosed in its Phase 1b/2 clinical trial evaluating the combination of samuraciclib (CT7001), an investigational oral and first-in-class inhibitor of CDK7, and vepdegestrant…

Read More

Flamingo Therapeutics Announces First Patient Dosed in Phase II PEMDA-HN Study for Head and Neck Squamous Cell Carcinoma (HNSCC)

02/16/2024

Excerpt from the Press Release: LEUVEN, Belgium and STRASBOURG, France and PHILADELPHIA, Feb. 14, 2024 /PRNewswire/ — Flamingo Therapeutics (“Flamingo”) today announced that the first patient has been dosed in its PEMDA-HN trial evaluating danvatirsen in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Flamingo’s…

Read More

Anti-Cancer Drugs Publishes Preclinical Data Demonstrating the Broad Antineoplastic Activity of Panavance’s Misetionamide (GP-2250)

02/13/2024

Misetionamide showed broad antineoplastic activity in 15 different cancer types including multiple human cancer cell lines with no detrimental effect on normal cells Misetionamide reduces energy metabolism by inhibiting aerobic glycolysis Excerpt from the Press Release: BERWYN, PA, Feb. 01, 2024 (GLOBE NEWSWIRE) — Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company…

Read More

Evidence From First Mahana Tinnitus Study Accepted for Presentation at Upcoming American Audiology Society (AAS) Annual Meeting

02/12/2024

Excerpt from the Press Release: SAN FRANCISCO, USA – February 1, 2024 – Mahana Therapeutics, a leading provider of digital therapeutics, announced today that positive results from a large US-based Pilot Clinical Trial, have been accepted for presentation at the upcoming American Audiology Society (AAS) Scientific and Technology Meeting, on February 15-17, 2024 in Scottsdale,…

Read More

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

02/09/2024

Preclinical Studies Show DA-1726 Elicits Superior Weight Loss Compared to Semaglutide (Wegovy™) and Similar Weight Loss Compared to Tirzepatide (Mounjaro™), While Consuming More Food Initiation of Phase 1 Clinical Trial Expected to Occur in the First Half of 2024 Excerpt from the Press Release: CAMBRIDGE, Mass., Feb. 1, 2024 /PRNewswire/ — NeuroBo Pharmaceuticals, Inc. (Nasdaq:…

Read More

Aviceda Therapeutics Announces First Patient Dosed in Part 2 of the Phase 2/3 SIGLEC Clinical Trial Assessing AVD-104 for the Treatment of Geographic Atrophy

02/08/2024

Part 2 of the Phase 2/3 SIGLEC clinical trial is designed and powered to serve as the first pivotal trial to support approval of AVD-104 in geographic atrophy. Part 2 of SIGLEC is expected to enroll approximately 300 patients who will be randomly assigned to two arms of AVD-104 or active comparator (avacincaptad pegol) and…

Read More

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine

02/07/2024

Excerpt from the Press Release: CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that interim results from the Phase 1 portion of the Phase 1/2 study of NTLA-2002 were published online in the New England Journal of…

Read More

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

02/06/2024

– Participants treated with atacicept for 72 weeks showed consistent and sustained reductions in Gd-IgA1, hematuria, and UPCR, with stable eGFR over the duration of treatment – Placebo cohort participants who crossed over to atacicept 150 mg in the OLE had similar outcomes at 72 weeks as atacicept cohort in the first 36 weeks of…

Read More